

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (currently amended). An immunogenic composition comprising

- i) at least one peptide, 29 amino acids in length, and corresponding to a fragment of TGF- β capable of eliciting an immunostimulating effect in an individual, and
- ii) at least one immunogenic determinant against which it is desirable to elicit an immunogenic response,

wherein said at least one fragment of TGF- β and said at least one immunogenic determinant are not identical, and wherein said fragment of TGF- β is identical to SEQ ID NO:1, or differs therefrom solely by a single amino acid substitution.

2-5 (cancelled).

6 (withdrawn). The immunogenic composition according to claim 1, wherein said substitution is a conservative amino acid substitution.

7 (withdrawn). The immunogenic composition according to claim 6, wherein said glycine (Gly) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Ala, Val, Leu, and Ile.

8 (withdrawn-currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said alanines~~ (Ala) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Gly, Val, Leu, and Ile.

9 (withdrawn). The immunogenic composition according to claim 6, wherein said valine (Val) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Leu, and Ile.

10 (withdrawn-currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said~~ leucines (Leu) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Val, and Ile.

11 (withdrawn). The immunogenic composition according to claim 6, wherein said isoleucine (Ile) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Val and Leu.

12 (withdrawn-currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said~~ aspartic acids (Asp) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Glu, Asn, and Gln.

13 (withdrawn - currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said~~ phenylalanines (Phe) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Tyr, Trp, His, Pro, ~~and preferably selected from the group of amino acids consisting of Tyr and Trp.~~

14 (withdrawn - currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said~~ tyrosines (Tyr) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Phe, Trp, His, Pro, ~~and preferably selected from the group of amino acids consisting of Phe and Trp.~~

15 (withdrawn-currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said~~ arginines (Arg) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Lys and His.

16 (withdrawn). The immunogenic composition according to claim 6, wherein said lysine (Lys) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Arg and His.

17 (withdrawn-currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said~~ asparagines (Asn) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, and Gln.

18 (withdrawn). The immunogenic composition according to claim 6, wherein said glutamine (Gln) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, and Asn.

19 (withdrawn). The immunogenic composition according to claim 6, wherein said proline (Pro) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Phe, Tyr, Trp, and His.

20 (withdrawn-currently amended). The immunogenic composition according to claim 6, wherein ~~at least one of said~~ cysteines (Cys) of said fragment of TGF- β is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, and Tyr.

21 (previously presented). The immunogenic composition according to claim 1, wherein said immunostimulating effect is characterised by an enhanced antibody response.

22 (currently amended). The immunogenic composition according to claim 1, wherein said immunostimulating effect is characterised by a cytotoxic T cell response.

23 (original). The immunogenic composition according to claim 21, wherein said response is caused by an increase in at least one class of immunoglobulins.

24 (original). The immunogenic composition according to claim 23, wherein said increase involves a plurality of immunoglobulin classes.

25 (cancelled).

26 (currently amended). The immunogenic composition according to claim ~~23~~ 22, wherein said response is caused by an increase in the level of cytotoxic T-cells.

27 (original). The immunogenic composition according to

claim 1, wherein said fragment and said immunogenic determinant are both non-conjugated.

28 (original). The immunogenic composition according to claim 1, wherein said fragment is conjugated and said immunogenic determinant is non-conjugated.

29 (original). The immunogenic composition according to claim 1, wherein said fragment is non-conjugated and said immunogenic determinant is conjugated.

30 (original). The immunogenic composition according to claim 1, wherein said fragment and said immunogenic determinant are both conjugated.

31 (original). The immunogenic composition according to claim 30, wherein said fragment is conjugated to said immunogenic determinant.

32 (original). The immunogenic composition according to claim 1 further comprising a carrier.

33 (original). The immunogenic composition according to claim 32, wherein said fragment and said immunogenic determinant are both non-conjugated.

34 (original). The immunogenic composition according to claim 33, wherein said carrier is non-conjugated.

35 (original). The immunogenic composition according to claim 33, wherein said carrier is conjugated.

36 (original). The immunogenic composition according to claim 32, wherein said fragment is conjugated and said immunogenic determinant is non-conjugated.

37 (original). The immunogenic composition according to claim 36, wherein said carrier is non-conjugated.

38 (original). The immunogenic composition according to claim 36, wherein said carrier is conjugated

39 (original). The immunogenic composition according to claim 38, wherein said fragment is conjugated to said carrier.

40 (original). The immunogenic composition according to claim 32, wherein said fragment is non-conjugated and said immunogenic determinant is conjugated.

41 (original). The immunogenic composition according to claim 40, wherein said carrier is non-conjugated.

42 (currently amended). The immunogenic composition according to claim 40, wherein said carrier is conjugated.

43 (original). The immunogenic composition according to claim 42, wherein said immunogenic determinant is conjugated to said carrier.

44 (original). The immunogenic composition according to claim 32, wherein said fragment and said immunogenic determinant are both conjugated.

45 (original). The immunogenic composition according to claim 44, wherein said fragment is conjugated to said immunogenic determinant.

46 (previously presented). The immunogenic composition according to claim 44, wherein said carrier is non-conjugated.

47 (previously presented). The immunogenic composition according to claim 44, wherein said carrier is conjugated.

48 (original). The immunogenic composition according to claim 47, wherein said fragment is conjugated to said carrier.

49 (original). The immunogenic composition according to claim 47, wherein said immunogenic determinant is conjugated to said carrier.

50 (original). The immunogenic composition according to claim 47, wherein said carrier is conjugated to said fragment and to said immunogenic determinant.

51 (previously presented). The immunogenic composition according to claim 1 further comprising an adjuvant.

52 (withdrawn). The immunogenic composition according to claim 1, wherein said addition or deletion is an addition or a deletion of from 2 to 10 amino acids.

53 (previously presented). A vaccine comprising the immunogenic composition according to claim 1.

54-56 (cancelled).

57 (withdrawn). A method of immunising an individual in need of immunisation, said method comprising the steps of

USSN - 09/822,873

- i) providing an immunogenic composition according to claim 1, and
- ii) administering said immunogenic composition to said individual.

58 (withdrawn). The method according to claim 57, wherein at least 50 % of individuals exposed to said immunogenic composition or vaccine are immunised.

59-60 (cancelled).